Phase 1 study in healthy participants of the safety, pharmacokinetics, and pharmacodynamics of enpatoran (M5049), a dual antagonist of toll‐like receptors 7 and 8

Phase 1 study in healthy participants of the safety, pharmacokinetics, and pharmacodynamics of enpatoran (M5049), a dual antagonist of toll‐like receptors 7 and 8

Abstract This study evaluated the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of single and multiple oral doses of enpatoran (formerly named M5049), a new toll‐like receptor (TLR) 7 and 8 dual antagonist, and the effect of food on a single dose in healthy participants. In...

Full description

Bibliographic Details
Main Authors: Andreas Port, Jamie V. Shaw, Lena Klopp‐Schulze, Afrim Bytyqi, Claudia Vetter, Elizabeth Hussey, Nadra Mammasse, Victor Ona, Angelika Bachmann, Denis Strugala, Christian Reh, Kosalaram Goteti
Format: Article
Language:English
Published: Wiley 2021-10-01
Series:Pharmacology Research & Perspectives
Subjects:
autoimmune diseases
pharmacodynamics
pharmacokinetics
safety
toll‐like receptors
Online Access:https://doi.org/10.1002/prp2.842

Internet

https://doi.org/10.1002/prp2.842

Similar Items